However, after adjusting for the false discovery rate, the Weighted median method showed that Interleukin-10 receptor subunit beta was associated with a lower risk of prostate cancer (OR: 0.93, 95% CI: 0.90–0.97, P < 0.001, PFDR = 0.03). Here, IL10RB is linked to prostate cancer.